The role of adrenergic and dopamine receptors.
Goldberg
L I
LI
Rajfer
S I
SI
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003846:Deoxyepinephrine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D011941:Receptors, Adrenergic / Q000187:drug effects / Q000502:physiology*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*
D000316:Adrenergic alpha-Agonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D011941:Receptors, Adrenergic; D011954:Receptors, Dopamine; D004280:Dobutamine; D007980:Levodopa; C023487:ibopamine; D003846:Deoxyepinephrine; D004298:Dopamine